Abstract
Immunotherapy with modified T cells to express chimeric antigen receptor (CAR) has been proven effective in remission of acute lymphoblastic leukemia (ALL) in children and young adults. The CAR possess an extracellular domain derived from antibody variable regions, and intracellular domains of T cell costimulation. CD19 protein has been shown to be an ideal target for therapies with CAR b…